Traditional supplements follow a one-size-fits-all approach, often leading to vitamin and mineral imbalances in the body. Bioniq solves this by creating personalised supplements based on blood biomarker data and individual factors like age, weight, gender, lifestyle, and health goals. The company combines cutting-edge AI technology with extensive biochemical data to deliver precise nutrient dosing tailored to each user’s profile.
This approach has gained significant traction among athletes. Cristiano Ronaldo became a major investor in October 2024, bringing Bioniq’s valuation to $82 million. Now, Manchester United and Portugal national team right-back Diogo Dalot has invested over €1 million in the company. This investment advances Bioniq’s mission to make personalised health accessible worldwide. When asked, Bioniq did not disclose the new valuation to TFN.
“The funds will enhance our algorithms, expand our research and development efforts, and diversify our product lineup to offer customers even more tailored solutions. This investment will further accelerate Bioniq’s global expansion, particularly in the U.S. market, where we’ve seen significant growth,” shared Vadim Fedotov, CEO and founder of Bioniq, with us.
Transforming supplements through data
Founded by Vadim Fedotov in London in 2019, Bioniq leads the industry in AI-driven personalised supplements based on blood test data. Through extensive testing, the company has built the largest proprietary biochemical database containing blood test data from customers across five continents. This database enables Bioniq to create more than 10 million possible formula combinations, each precisely tailored to individual bodies and health goals.
Speaking with TFN, Fedotov noted: “Bionic was born from a combination of personal experience and a clear market need. As a former professional athlete and health enthusiast, I worked with top sports scientists, tracking my biomarkers to optimise performance and recovery. I witnessed firsthand how powerful personalised health data could be — yet this level of precision remained largely inaccessible to the public.”
He added: “I wanted to change that. We created Bioniq to bring science-driven, data-backed personalisation to everyone, shifting from reactive treatment to proactive health management. While the market was flooded with generic supplements, people had vastly different health needs. By combining blood analysis with AI-driven recommendations, we built a system that adapts to each individual, delivering exactly what their body needs.”
Originally developed by scientists to enhance Olympic athletes’ physical and cognitive function, Bioniq now serves customers in 70 countries, with its user base growing tenfold in 2024. The company leads the expanding supplements market, which was valued at $177.50 billion in 2023 and is projected to grow at a CAGR of 9.1% from 2024 to 2030.
Behind Bioniq: customisable formulas for athletes
Discussing Bioniq’s competitive edge, Fedotov explained: “At Bioniq, we’ve developed a unique approach combining blood analysis with AI-driven insights to create truly personalised supplements. Unlike traditional one-size-fits-all solutions, our technology identifies individual nutrient imbalances through biomarker data and adjusts formulations continuously. We’re also the only company considering BMI, weight, and height to determine precise micronutrient dosages, ensuring optimal absorption and effectiveness.”
Diogo Dalot, a dedicated Bioniq member for over four years and now its investor, has integrated the formula into his daily routine to optimise health and performance. He actively collaborates with the Bioniq team on product innovation, sharing insights as a professional athlete. Through Bioniq’s new Build Your Own supplement, Dalot has created an even more precise routine, adjusting his nutrient intake based on performance goals. While the PRO formula reduces inflammation, increases resilience, and improves endurance, his Build Your Own supplement allows mild inflammation for natural muscle building.
“In high-level performance, my biggest focus has always been finding that extra 1% — the key to setting myself apart. Since discovering Bioniq in 2022, it’s been a game-changer for me. I’ve seen the results firsthand. Such progress is only possible with a truly personalised product tailored to my needs,” said Dalot. “Now, I’m thrilled to become an investor. I believe in Bioniq’s mission and see tremendous potential, especially with the growing global demand for personalised nutrition.”
Shaping the future of sports nutrition
Bioniq has become the product of choice for many of the world’s top athletes, including Soccer World Cup Champions, NBA All-Stars, and Ironman winners. Its partnerships with leading health and sports institutions like Lanserhof and UFC further validate its effectiveness in enhancing performance and recovery.
Fedotov concludes, “We plan to disrupt the generic supplements market further and make Bioniq’s personalised approach the new norm. With our commitment to innovation and customer satisfaction, we aim to make proactive health management accessible to everyone, not just athletes.”
The post AI-driven supplements are the future? Manchester United’s Dalot invests over €1M in Bioniq, joining Ronaldo appeared first on Tech Funding News.